Merck said it is leaning toward a lower Winrevair dose in a pivotal Phase 3 trial for a rare form of heart failure after observing a “pretty profound” benefit at the lowest dose in its earlier Phase 2 study. The shift highlights how Merck is using the Phase 2 dose response to shape the design of the confirmatory program for a population where prior options remain limited.